Niceritrol

Summary

Niceritrol is a niacin derivative used as a hypolipidemic agent. It is an ester of pentaerythritol and nicotinic acid, has general properties similar to those of nicotinic acid (Nicotinamide), to which it is slowly hydrolysed. Niceritrol has been used as a lipid regulating drug in hyperlipidaemias and as a vasodilator in the treatment of peripheral vascular disease.[1][2]

Niceritrol
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 3-[(pyridin-3-yl)carbonyloxy]-2,2-bis({[(pyridin-3-yl)carbonyloxy]methyl})propyl pyridine-3-carboxylate
CAS Number
  • 5868-05-3 checkY
PubChem CID
  • 4476
ChemSpider
  • 4321 ☒N
UNII
  • F54EHJ34MV
KEGG
  • D01754 checkY
CompTox Dashboard (EPA)
  • DTXSID1023364 Edit this at Wikidata
ECHA InfoCard100.025.017 Edit this at Wikidata
Chemical and physical data
FormulaC29H24N4O8
Molar mass556.531 g·mol−1
3D model (JSmol)
  • Interactive image
  • C1=CC(=CN=C1)C(=O)OCC(COC(=O)C2=CN=CC=C2)(COC(=O)C3=CN=CC=C3)COC(=O)C4=CN=CC=C4
  • InChI=1S/C29H24N4O8/c34-25(21-5-1-9-30-13-21)38-17-29(18-39-26(35)22-6-2-10-31-14-22,19-40-27(36)23-7-3-11-32-15-23)20-41-28(37)24-8-4-12-33-16-24/h1-16H,17-20H2 ☒N
  • Key:KUEUWHJGRZKESU-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

References edit

  1. ^ Owada A, Suda S, Hata T (April 2003). "Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial". The American Journal of Medicine. 114 (5): 347–53. doi:10.1016/s0002-9343(02)01567-x. PMID 12714122.
  2. ^ Truven Health Analytics Inc. (May 8, 2008). "Niceritrol". Micromedexsolutions.com. Retrieved December 14, 2014.